Product Information
TOPAMAX 200 MG TABLET is a brand product labeled by Janssen Pharmaceuticals Inc., priced at $21.0706 per EA under NDC 50458064265. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 24, 1996. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Janssen Pharmaceuticals Inc.NDC
50458064265
Classification
Brand
Dosage Form
TABLET, COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
New Drug (NDA)
FDA Application
NDA020505FDA Approved
12/24/1996
TE Code
AB
On Market Since
1/1/1997
Pharmacological Classes
Price Statistics
The NADAC for TOPAMAX 200 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 87.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $21.0706 per EA |
|---|---|
| All-time high | $21.1011 (May 13, 2026) |
| All-time low | $11.2220 (Nov 28, 2013) |
| 52-week high | $21.1011 |
| 52-week low | $20.4744 |
| Median price | $18.8714 |
| Average price | $17.7241 |
| Largest weekly change | +9.9% (Jan 13, 2016) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Janssen Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPAMAX 200 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TOPAMAX 200 MG TABLET, manufactured by Janssen Pharmaceuticals Inc., is $21.0706 per EA (NDC 50458064265), effective Sep 30, 2026.
How has the price of TOPAMAX 200 MG TABLET changed over time?
Over the history we have for it, the NADAC for TOPAMAX 200 MG TABLET has risen 87.8%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TOPAMAX 200 MG TABLET?
Since Nov 28, 2013, the NADAC for TOPAMAX 200 MG TABLET has ranged from a low of $11.2220 (Nov 28, 2013) to a high of $21.1011 (May 13, 2026), with a median of $18.8714 per EA.
Are there cheaper alternatives to TOPAMAX 200 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE 200 MG TABLET, is $0.1102 per EA — about 99% below TOPAMAX 200 MG TABLET.
Who manufactures TOPAMAX 200 MG TABLET?
TOPAMAX 200 MG TABLET (NDC 50458064265) is labeled by Janssen Pharmaceuticals Inc., and CMS classifies it as a brand product.